Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 265 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatic Insufficiency Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

NCT02998775
View directory record Official record
Conditions
Hepatic Impairment; Renal Impairment
Interventions
Plasma Sampling
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 3 Interventional

Improving Clinician Communication Skills (ICCS)

NCT00687349
View directory record Official record
Conditions
Advanced Cancer, Chronic Obstructive Pulmonary Disease (COPD), Restrictive Lung Disease, Congestive Heart Failure, End Stage Liver Disease
Interventions
Training Program Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Charleston, South Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 24, 2026, 9:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

NCT00859053
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BMS-790052
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Anaheim, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 24, 2026, 9:39 AM EDT
Completed No phase listed Observational

NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients

NCT04548596
View directory record Official record
Conditions
Traumatic Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Liver Failure, Ischemic Stroke
Interventions
Transcranial Doppler
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
3
States / cities
Davis, California • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 24, 2026, 9:39 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

NCT01846663
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

NCT00558038
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
AST-120, lactulose
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Not applicable Interventional

Effect of Brief Dietary Intervention on Ammonia Levels

NCT05376488
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
One meal
Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

NCT01767103
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Ferriprox®
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced Oct 24, 2026, 9:39 AM EDT
Not listed No phase listed Observational

Flicker App for Minimal Hepatic Encephalopathy

NCT04415294
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Critical flicker frequency
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 24, 2026, 9:39 AM EDT
Completed No phase listed Observational

Adult-to-Adult Living Donor Transplant Cohort Study

NCT01619475
View directory record Official record
Conditions
Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C, Liver Cirrhosis
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
18 Years and older
Enrollment
1,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Liver Live Donor Champion Program

NCT03580629
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Liver Live Donor Champion Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 24, 2026, 9:39 AM EDT
Recruiting Phase 1Phase 2 Interventional

TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation

NCT07634562
View directory record Official record
Conditions
Liver Failure
Interventions
Anti-Thymocyte Globulin, ATG (Rabbit), Total lymphoid irradiation
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Not applicable Interventional

CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis

NCT04205396
View directory record Official record
Conditions
Caregivers
Interventions
Written emotional disclosure, Resilience training, No treatment
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation

NCT05045794
View directory record Official record
Conditions
End Stage Liver DIsease, Liver Failure
Interventions
VitaSmart™Liver Machine Perfusion System, Static cold storage
Device · Other
Lead sponsor
Bridge to Life Ltd.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
San Bernadino, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 9:39 AM EDT
Recruiting No phase listed Observational

Functional Assessment in Liver Transplantation

NCT03228290
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
12
States / cities
Little Rock, Arkansas • Loma Linda, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 9:39 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Understanding Patient's Knowledge and Use of Acetaminophen

NCT00823758
View directory record Official record
Conditions
Liver Failure
Interventions
Focus Groups, Personal Interviews
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2020
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 24, 2026, 9:39 AM EDT
Withdrawn Phase 3 Interventional

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

NCT02086825
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

NCT06402721
View directory record Official record
Conditions
Chronic Kidney Disease, Hepatic Impairment
Interventions
BAY3283142
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 24, 2026, 9:39 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 24, 2026, 9:39 AM EDT
Terminated Phase 4 Interventional Results available

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

NCT00896025
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 24, 2026, 9:39 AM EDT